TARRYTOWN, N.Y.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it has completed enrollment and dosing in a phase 1b clinical trial of PRO 140, a new investigational HIV therapy. PRO 140 is a humanized monoclonal antibody that binds CCR5, a principal portal used by HIV to enter cells and a promising target for a new generation of HIV therapies. PRO 140 is a viral-entry inhibitor, designed to prevent HIV from entering and infecting immune system cells. This phase 1b trial was designed to evaluate the tolerability, pharmacology and antiviral activity of PRO 140 in patients infected with HIV.
